Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Comparator Condition Clear all
Recruiting Phase 2 Interventional

Oxytocin Effects on Bone in Children With Autism Spectrum Disorder

NCT05754073
View directory record Official record
Conditions
Autism Spectrum Disorder, Bone Health
Interventions
1. Intranasal oxytocin spray, 2. Intranasal placebo spray, 3. Intranasal Oxytocin spray
Drug
Lead sponsor
Elizabeth Austen Lawson
Other
Eligibility
6 Years to 18 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Not yet recruiting Phase 4 Interventional

Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking

NCT07328594
View directory record Official record
Conditions
Smoking, Nicotine, Tobacco, Addiction, Substance Use Disorders, Insomnia, Sleep
Interventions
Daridorexant 50 mg, Placebo
Drug · Other
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Phase 3 Interventional

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

NCT04513912
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Matching placebo to Seltorexant, Quetiapine XR, Matching placebo to Quetiapine XR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
75
States / cities
Birmingham, Alabama • Tucson, Arizona • Culver City, California + 62 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Not applicable Interventional Results available

Depression and Congestive Heart Failure in Outpatients.

NCT00321269
View directory record Official record
Conditions
Heart Failure, Depression
Interventions
Single Illness Management, Comorbid Illness Management
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Iowa City, Iowa • Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 3, 2026, 1:16 AM EDT
Recruiting Phase 3 Interventional

Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

NCT07284602
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Deupirfenidone, Pirfenidone (PFD)
Drug
Lead sponsor
PureTech
Industry
Eligibility
40 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Palm Spring, California • Redding, California • North Dartmouth, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Not applicable Interventional

Testing a Causal Model of Cognitive Control Deficits in Posttraumatic Stress Disorder (PTSD)

NCT06016673
View directory record Official record
Conditions
PTSD
Interventions
Transcranial Magnetic Stimulation (TMS)
Procedure
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2024 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers

NCT00748956
View directory record Official record
Conditions
Mood Disorder, Anxiety Disorders
Interventions
Low dose NPY, High dose NPY, Placebo
Drug
Lead sponsor
Dennis Charney
Other
Eligibility
25 Years to 45 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 3, 2026, 1:16 AM EDT
Recruiting Phase 3 Interventional

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

NCT07217301
View directory record Official record
Conditions
IO-resistant sqNSCLC
Interventions
TAK-928, Control Arm
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Jonesboro, Arkansas • Fair Oaks, California • Fountain Valley, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions

NCT01188057
View directory record Official record
Conditions
Healthy
Interventions
ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, NIRAVAM TM 2 mg orally disintegrating tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 24, 2010 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Not applicable Interventional Results available

Adolescents With Substance Use Disorders Transitioníng From Residential Treatment to the Community

NCT03592186
View directory record Official record
Conditions
Substance Use, Adolescent Behavior
Interventions
Parenting Wisely+, Treatment as Usual
Behavioral
Lead sponsor
Brown University
Other
Eligibility
12 Years to 17 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Rockford, Illinois • Cranston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Not applicable Interventional

Internet-based Interacting Together Everyday, Recovery After Childhood TBI (I-InTERACT)--RRTC

NCT01214694
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT), Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express), Internet Resources Comparison (IRC)
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 9 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
Aurora, Colorado • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Sep 3, 2026, 1:16 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Implementation Strategies for Caregiver and Teacher Use of Behavioral Interventions: Aim 2

NCT07321327
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder Symptoms
Interventions
Positive Behavior Management Toolkit for Caregivers, Positive Behavioral Management Toolkit for Teachers
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)

NCT03268941
View directory record Official record
Conditions
Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
Interventions
TAK-906 Maleate, Metaclopramide, TAK-906 Maleate Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Peoria, Arizona • Tucson, Arizona • Little Rock, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 3, 2026, 1:16 AM EDT
Terminated Not applicable Interventional

Contingency Management for Smoking Cessation Among Veterans With Psychotic Disorders

NCT00508560
View directory record Official record
Conditions
Nicotine Dependence, Psychotic Disorders
Interventions
Contingency Management, Reward
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Sep 3, 2026, 1:16 AM EDT
Recruiting Phase 2 Interventional

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

NCT07333183
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions
inhaled mosliciguat, Dry Powder Inhaler
Drug · Device
Lead sponsor
Pulmovant, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Santa Barbara, California • Torrance, California • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT00829374
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo comparator
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
52
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Phase 3 Interventional

Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations

NCT00203034
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate, 1.0 mg rasagiline mesylate, Placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Results available

Vitamin D for Sickle-cell Respiratory Complications

NCT01443728
View directory record Official record
Conditions
Sickle Cell Disease, Vitamin D Deficiency, Acute Chest Syndrome, Asthma, Respiratory Infections
Interventions
Experimental: Vitamin D3 100,000 IU, Active Comparator: Vitamin D3 12,000 IU
Drug
Lead sponsor
Gary M Brittenham, MD
Other
Eligibility
3 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Not applicable Interventional

Efficacy of Brief Acceptance and Commitment Therapy (ACT) for Perinatal Anxiety

NCT03837392
View directory record Official record
Conditions
Post Partum Depression, Perinatal Depression, Post Partum Anxiety, Perinatal Anxiety
Interventions
Baseline Assessment (18-26 weeks pregnant), Online Intervention and Phone Coaching Interventions, Follow Up Assessments: 34-36 weeks pregnant and 4-week postpartum, Follow Up Assessments: 8 weeks postpartum
Diagnostic Test · Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Sep 3, 2026, 1:16 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Tdap and Biomarkers of Alzheimer's Disease

NCT05183516
View directory record Official record
Conditions
Alzheimer Disease, Late Onset
Interventions
tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
Biological
Lead sponsor
Mindful Diagnostics and Therapeutics, LLC
Industry
Eligibility
50 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Eau Claire, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers

NCT00864604
View directory record Official record
Conditions
Healthy
Interventions
Nabumetone 750 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 3, 2026, 1:16 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests.

NCT07089836
View directory record Official record
Conditions
Treponema Pallidum, Treponema Pallidum Infection, Syphilis Infection, Serum, Plasma, Blooddraw, Sexually Transmitted Infection (STI)
Interventions
ALPCO Syphilis-T, ALPCO Syphilis-NT CLIA Kits
Device
Lead sponsor
American Laboratory Products Company
Industry
Eligibility
13 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
6
States / cities
Lancaster, California • Los Angeles, California • North Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 3, 2026, 1:16 AM EDT
Terminated Not applicable Interventional

Cognitive Enhancement Through Computerized Training

NCT04244032
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Working Memory Training, Inhibitory Control Training, Bias Modification Training
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
25 Years to 64 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 3, 2026, 1:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Emotion Study/Substudy: Flexible Brain Study

NCT03872414
View directory record Official record
Conditions
Aging, Emotions, Parkinson Disease
Interventions
Anterior cingulate cortex activation, Primary auditory cortex activation
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 3, 2026, 1:16 AM EDT